2B70:F:F-iShares NASDAQ US Biotechnology UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 5.592

Change

-0.03 (-0.57)%

Market Cap

USD 0.52B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-24 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.26 (+0.97%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

+0.59 (+1.17%)

USD 115.04B
FRCJ:F UBS MSCI Japan Socially Respon..

+0.24 (+1.10%)

USD 83.57B
SXR8:F iShares Core S&P 500 UCITS ETF..

+5.28 (+1.06%)

USD 80.45B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

+0.54 (+0.99%)

USD 76.57B
EUNL:F iShares Core MSCI World UCITS ..

+0.93 (+1.04%)

USD 72.04B
SXRZ:F iShares VII PLC - iShares Nikk..

+2.95 (+1.29%)

USD 58.19B
XDNY:F Xtrackers MSCI Japan ESG Scree..

+0.16 (+1.06%)

USD 56.18B
VUSA:F Vanguard Funds Public Limited ..

+0.93 (+1.04%)

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.92 (+1.04%)

USD 49.95B

ETFs Containing 2B70:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.86% 28% F 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.86% 26% F 41% F
Trailing 12 Months  
Capital Gain 4.35% 44% F 56% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 4.35% 42% F 51% F
Trailing 5 Years  
Capital Gain 31.21% 59% D- 63% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.21% 58% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 6.85% 74% C 70% C-
Dividend Return 6.85% 73% C 64% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 14.84% 39% F 69% C-
Risk Adjusted Return 46.16% 73% C 76% C+
Market Capitalization 0.52B 63% D 50% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.